
Sanja Andric Petrovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/271233/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	4.5	14
2	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	4.8	10
3	Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use. Frontiers in Psychiatry, 2022, 13, 796719.	2.6	0
4	The FKBP5 genotype and childhood trauma effects on FKBP5 DNA methylation in patients with psychosis, their unaffected siblings, and healthy controls. Psychoneuroendocrinology, 2021, 128, 105205.	2.7	7
5	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
6	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	4.5	28
7	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	3.9	36
8	S211. LONG-TERM BENZODIAZEPINE USE DURING MAINTENANCE THERAPY OF PSYCHOSIS - ASSOCIATION WITH SYMPTOMS, COGNITION AND FUNCTIONALITY. Schizophrenia Bulletin, 2020, 46, S119-S119.	4.3	0
9	Maintenance phase treatment of psychotic disorders in outpatients from Serbia – focus on long-term benzodiazepine use. International Journal of Psychiatry in Clinical Practice, 2020, 24, 315-321.	2.4	6
10	Duration of psychiatric appointments for patients with Psychosis spectrum disorders in Serbia: Is it significantly prolonged by DIALOG+ psychosocial intervention?. Psihijatrija Danas, 2020, 52, 13-24.	0.1	0
11	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 853-858.	1.7	11
12	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	4.3	46
13	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	2.6	5
14	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	10.4	127
15	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. Microbial Biotechnology, 2019, 13, 1283-1288.	1.7	5
16	Sex differences in facial emotion recognition in health and psychotic disorders. Cognitive Neuropsychiatry, 2019, 24, 108-122.	1.3	11
17	The classification of psychotic disorders: Trending topics. Engrami, 2019, 41, 85-100.	0.1	1
18	Openness to experience shortens duration of untreated psychosis in Serbian clinical population.	1.7	2

Microbial Biotechnology, 2018, 12, 91-95.

#	Article	IF	CITATIONS
19	Executive function in treatment-resistant depression before and after electroconvulsive therapy. World Journal of Biological Psychiatry, 2017, 18, 624-632.	2.6	2
20	Prescribing practices in Southeastern Europe – focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals. Psychiatry Research, 2017, 258, 59-65.	3.3	19
21	European status and perspectives on early detection and intervention in at-risk mental state and first episode psychosis: Viewpoint from the EPA section for prevention of mental disorders. European Psychiatry, 2017, 46, 48-50.	0.2	10
22	The emerging role of the FKBP5 gene polymorphisms in vulnerability–stress model of schizophrenia: further evidence from a Serbian population. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 527-539.	3.2	20
23	The acute and medium-term effects of treatment with electroconvulsive therapy on memory in patients with major depressive disorder. Psychological Medicine, 2016, 46, 797-806.	4.5	23
24	Familial covariation of facial emotion recognition and IQ in schizophrenia. Psychiatry Research, 2016, 246, 52-57.	3.3	18
25	Neuroticism and facial emotion recognition in healthy adults. Microbial Biotechnology, 2016, 10, 160-164.	1.7	17
26	»Treatment Resistance« Enigma Resolved by Pharmacogenomics â^' A Case Study of Clozapine Therapy in Schizophrenia / Enigma »Terapo-Rezistence« Razrešena Uz Pomoć Farmakogenomike - Prikaz Slućaja Terapije Klozapinom U Shizofreniji. Journal of Medical Biochemistry, 2015, 34, 223-227.	1.7	7
27	The role of glucocorticoid receptor phosphorylation in the model of negative affective states. World Journal of Biological Psychiatry, 2015, 16, 301-311.	2.6	8
28	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
29	Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40,	4.8	25